Welcome to our dedicated page for Albemarle news (Ticker: ALB), a resource for investors and traders seeking the latest updates and insights on Albemarle stock.
Albemarle Corporation reports news on its role as a global producer of lithium and bromine used in mobility, energy, connectivity and health applications. Company updates commonly cover Energy Storage and Specialties performance, lithium market pricing and volumes, bromine-based solutions, operational productivity, and cash generation.
Recurring developments also include quarterly earnings releases, common stock dividends, debt tender offers and note redemptions, board and committee appointments, and portfolio actions. Recent corporate updates include the completed sale of a controlling stake in Ketjen's refining catalyst solutions business, Albemarle's retained minority interest in Ketjen, and the integration of Performance Catalyst Solutions into Albemarle's product portfolio.
Albemarle (NYSE: ALB) reported Q4 2025 net sales of $1.4 billion, up 16% year-over-year, and a Q4 net loss of ($414) million, or ($3.87) per share, driven by tax items and a Ketjen-related asset write-down. Adjusted EBITDA was $269 million, up 7%.
Full-year 2025 cash from operations was $1.3 billion, free cash flow $692 million, capex $590 million, and the company expects FY2026 outcomes across lithium price scenarios with capex ~ $550–$600 million.
Albemarle (NYSE: ALB) will release its fourth quarter 2025 earnings after the NYSE close on Wednesday, February 11, 2026. The company will host a conference call to discuss results on Thursday, February 12, 2026 at 8:00 a.m. EST, accessible via webcast or direct dial (Conference ID: ALBQ4).
Participant dial-in numbers and an attendee URL are provided for live access, and a webcast replay will be available after the event on Albemarle's News and Events/investor website.
Lithium Royalty Corp (TSX: LIRC) congratulated Power Metals on a cesium concentrate offtake agreement between Power Metals and Albemarle (NYSE: ALB), including a prepayment facility of up to C$5 million. LIRC holds a 2.0% gross overriding royalty on the Case Lake project, which hosts a maiden inferred cesium resource of 13,000 tonnes at 2.4% Cs2O (0.1% cutoff) from West Joe Dyke. Power Metals reaffirmed a 2026 production target and reported exploration upside with an additional target of 11,000–15,000 tonnes plus 17 untested targets. Management cited project capital requirements of under C$8 million.
Albemarle (NYSE: ALB) reported third-quarter 2025 results for the period ended September 30, 2025. Net sales were $1.3 billion, Adjusted EBITDA was $225.6 million (up 6.7% YoY) and the company reported a net loss of ($161) million, or ($1.72) per diluted share. On an adjusted basis, diluted loss was ($0.19) per share excluding a Ketjen goodwill impairment. Cash from operations for Q3 was $356 million (up 57% YoY); year-to-date cash from operations was $894 million.
Management reduced full-year capex to ~ $600 million, expects positive free cash flow of $300–$400 million for 2025, and announced combined pre-tax proceeds of ~ $660 million from sale agreements for stakes in Ketjen and Eurecat.
Albemarle (NYSE: ALB) declared a quarterly common stock dividend of $0.405 per share, equal to an annualized rate of $1.62. The dividend is payable on January 2, 2026 to shareholders of record at the close of business on December 12, 2025.
The announcement reiterates Albemarle's routine shareholder distribution practice and includes forward-looking cautionary language about factors that could cause actual results to differ from expectations.
KPS Capital Partners will acquire a controlling stake in Ketjen from Albemarle (NYSE: ALB), with KPS and Albemarle affiliates owning approximately 51% and 49% of Ketjen at closing, respectively.
KPS will hold a majority of the board and operational control. Albemarle will retain 100% of Ketjen's Performance Catalyst Solutions (PCS) business. The transaction is expected to close in Q1 2026 and is subject to customary closing conditions and approvals.
Ketjen is headquartered in Houston, has ~840 employees, two manufacturing facilities, two research and technology centers and two joint ventures across the Americas, Europe and Asia. Committed debt financing was provided by Barclays, Jefferies, BNP Paribas and Santander.
Albemarle (NYSE: ALB) agreed to sell a controlling 51% stake in Ketjen's refining catalyst solutions business to KPS Capital Partners and to sell its 50% interest in the Eurecat joint venture to Axens.
Albemarle will retain ~49% of Ketjen and 100% of Ketjen's Performance Catalyst Solutions business, including the Pasadena, Texas plant. Both transactions are expected to close in H1 2026, subject to regulatory approvals, and are expected to generate approximately $660 million pre-tax in total proceeds, which Albemarle expects to use for debt reduction and general corporate purposes.
Ketjen (NYSE:ALB) agreed to sell its 50% ownership stake in Eurecat to Axens and to transfer Ketjen’s Isomerization Catalysts business to Axens, subject to regulatory approval. Axens will assume full ownership of Eurecat and Ketjen will extend a long‑term collaboration with Eurecat on regeneration, rejuvenation, ex‑situ sulfiding, and spent catalyst processing. Eurecat will continue serving all operators and catalyst manufacturers while collaborating with Ketjen on advanced catalyst technologies. Axens said it will pursue initiatives to advance catalyst circularity, ex‑situ activation, and reduce carbon footprint in catalyst management and activation.
Albemarle Corporation (NYSE: ALB), a global leader in essential elements for mobility, energy, connectivity and health, has scheduled its Q3 2025 earnings release for November 5, 2025, after NYSE market close.
The company will host a conference call to discuss the results on November 6, 2025, at 8:00 AM EST. Investors can access the call via webcast through Albemarle's investor relations website or through direct dial numbers provided for both U.S. & international participants.
A webcast replay will be made available on Albemarle's investor website following the event.
Ketjen (NYSE:ALB) has unveiled SaFeGuard™, a breakthrough catalyst technology designed to combat iron poisoning in FCC units. A 30-day commercial trial demonstrated remarkable results, including a 77% improvement in accessibility with just 50% inventory replacement. The technology enables processing of heavy iron-rich feedstocks and improves unit activity.
The innovative solution minimizes Eutectic formation to maintain open catalyst pores, potentially delivering up to 130% increase in accessibility with full inventory changeout. SaFeGuard™ effectively handles multiple contaminants including nickel, vanadium, calcium, sodium, and silicon, making it suitable for processing various feedstocks including heavy, resid, tight oil, and renewable feeds.